← Back to Search

Radioactive Iodine

Radioactive Iodine Dosimetry for Thyroid Cancer

Phase 1
Waitlist Available
Led By Ravinder Grewal, MD
Research Sponsored by Memorial Sloan Kettering Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Adult thyroid carcinoma patients who have previously demonstrated radioiodine-avid metastases and are about to undergo Thyrogen-assisted dosimetry at MSKCC.
The patient and physician are planning to administer 131-I for therapy if persistent radioiodine-avid metastases are present.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up conclusion of the study
Awards & highlights

Study Summary

This trial is testing a slightly different form of radioactive iodine to see if it can more accurately predict which patients will not respond to the standard treatment.

Who is the study for?
This trial is for adults with thyroid cancer who've had their thyroid removed and previous treatment to eliminate remaining thyroid tissue. They must have metastases that absorb radioiodine, measurable disease documented in the last six months, and be planning further radioiodine therapy if needed. It's not for those under 18, pregnant, treated with radioiodine in the past nine months, or without metastases.Check my eligibility
What is being tested?
The study tests a radioactive iodine form called 124-I to predict radiation doses received by each cancer spread (metastatic lesion) using PET scans. This could help decide if patients will benefit from another type of radioactive iodine treatment (131-I), avoiding unnecessary exposure for non-responders.See study design
What are the potential side effects?
Radioactive iodine treatments like 124-I and 131-I can cause side effects such as dry mouth, neck pain due to thyroid inflammation, altered taste sensation, nausea or vomiting. Long-term risks may include increased chance of other cancers or fertility issues.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have thyroid cancer with metastases that respond to radioiodine and am scheduled for a specific diagnostic test at MSKCC.
Select...
I am considering 131-I treatment for my thyroid cancer metastases.
Select...
I had my thyroid removed due to cancer and underwent treatment to destroy leftover thyroid tissue.
Select...
I belong to any race, ethnicity, and religious background.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~conclusion of the study
This trial's timeline: 3 weeks for screening, Varies for treatment, and conclusion of the study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To estimate the relationship between the radiation dose and response to radiation at one year for metastatic lesions arising from differentiated thyroid carcinoma, following a single therapeutic administration of 131-Iodine.
Secondary outcome measures
To determine the diagnostic sensitivity of the 124-Iodine whole body scan based on the 131-Iodine post-therapy scan (the "gold-standard").

Trial Design

1Treatment groups
Experimental Treatment
Group I: 1Experimental Treatment1 Intervention
131 I-iodine (131-I), 124 I-iodine (124-I)

Find a Location

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,928 Previous Clinical Trials
591,788 Total Patients Enrolled
Gustave Roussy, Cancer Campus, Grand ParisOTHER
253 Previous Clinical Trials
257,660 Total Patients Enrolled
Ravinder Grewal, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
4 Previous Clinical Trials
75 Total Patients Enrolled

Media Library

131 I-iodine (131-I) (Radioactive Iodine) Clinical Trial Eligibility Overview. Trial Name: NCT00673010 — Phase 1
Thyroid Cancer Research Study Groups: 1
Thyroid Cancer Clinical Trial 2023: 131 I-iodine (131-I) Highlights & Side Effects. Trial Name: NCT00673010 — Phase 1
131 I-iodine (131-I) (Radioactive Iodine) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00673010 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are 131 I-iodine (131-I) and 124 I-iodine (124-I) authorized by the FDA?

"Considering its Phase 1 status, there is limited evidence to suggest the safety and efficacy of 131 I-iodine (131-I) or 124 I-iodine(124-I), thus both score a 1 on our team's scale."

Answered by AI

Are there any vacancies available for participants of this research experiment?

"Reports on clinicaltrials.gov denote that this medical experiment, initially posted in March of 2005 and last reviewed April 1 2022, is not presently searching for study members. However, there are 230 other trials actively recruiting people to participate."

Answered by AI
~1 spots leftby Mar 2025